Showing results (1-10 of 59) with videos related to
Sort By:
Pageof 6
Clinical Lung Cancer|January 24, 2007
Gemcitabine/carboplatin in a modified 21-day administration schedule for advanced-stage non-small-cell lung cancerMana Yoshimura, Fumio Imamura, Kiyonobu Ueno, et al.Radiology Case Reports|March 8, 2021
Giant esophageal hemangioma diagnosed by 99mTc-HSA-D scintigraphy following equivocal CT, MRI, and endoscopyElly Arizono, Yu Tajima, Mana Yoshimura, et al.Clinical Nuclear Medicine|December 3, 2019
Adrenocortical Scintigraphy With SPECT/CT for the Diagnosis of Hepatic Adrenal RestMasako Kawasaki, Mana Yoshimura, Katsutoshi Sugimoto, et al.Kaku Igaku. the Japanese Journal of Nuclear Medicine|February 22, 2021
[The 42nd Report on Survey of the Adverse Reaction to Radiopharmaceuticals (The 45th Survey in 2019)], Hidehiko Okazawa, Tomoya Uehara, et al.Kaku Igaku. the Japanese Journal of Nuclear Medicine|February 15, 2023
[The 44th Report on Survey of the Adverse Reaction to Radiopharmaceuticals (The 47th Survey in 2021)], Hidehiko Okazawa, Tomoya Uehara, et al.Kaku Igaku. the Japanese Journal of Nuclear Medicine|February 21, 2024
[The 45th Report on Survey of the Adverse Reaction to Radiopharmaceuticals (The 48th Survey in 2022)], Hidehiko Okazawa, Tomoya Uehara, et al.Kaku Igaku. the Japanese Journal of Nuclear Medicine|March 24, 2022
[The 43rd Report on the Survey of Adverse Reactions to Radiopharmaceuticals (46th Survey in 2020)], Hidehiko Okazawa, Tomoya Uehara, et al.Kaku Igaku. the Japanese Journal of Nuclear Medicine|April 29, 2014
[The 35th Report on Survey of the Adverse Reaction to Radiopharmaceuticals (the 38th Survey in 2012)]Hiroshi Matsuda, Yasushi Arano, Hidehiko Okazawa, et al.Kaku Igaku. the Japanese Journal of Nuclear Medicine|October 28, 2015
[The 36th Report on Survey of the Adverse Reaction to Radiopharmaceuticals (The 39th Survey in 2013)]Hiroshi Matsuda, Yasushi Arano, Hidehiko Okazawa, et al.Kaku Igaku. the Japanese Journal of Nuclear Medicine|February 20, 2020
[The 41st Report on Survey of the Adverse Reaction to Radiopharmaceuticals (The 44th Survey in 2018)], Hiroshi Matsuda, Tomoya Uehara, et al.Pageof 6